Vasopressors Combination Therapy (Norepinephrine Plus Vasopressin Receptor Agonists) Improve Septic Shock Outcome: A Systematic Review and Meta-Analysis
In brief
In septic shock, added vasopressin-receptor drugs tied to 10% lower mortality
Across 21 trials involving 3,873 adults, adding vasopressin-receptor agonists to norepinephrine was associated with 10% lower mortality at the longest follow-up, but also more than twice the risk of digital ischemia. The evidence was rated low quality, and trial sequential analysis found no firm proof of benefit, so whether the survival difference is real remains uncertain.
- Journal
- Journal of intensive care medicine (Q1)
- Published
- 19 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Weijie Yu, Yanjie Zhang, Zhu Luo, Xiner Cai, Jiyue Shao, Wanting Lin, et al.
- PMID
- 42895627
- DOI
- 10.1177/08850666261500019
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 20 October 2026): Vasopressors combination therapy may reduce mortality in septic shock
Abstract
BackgroundStudies showed different results of vasopressors combination therapy in septic shock patients. This meta-analysis aimed to evaluate the outcomes of combination of norepinephrine plus vasopressin receptor agonists in adult septic shock.MethodsCochrane Library, Embase, Web of Science, and PubMed databases were searched up to September 27, 2026, to identify randomized controlled trials (RCTs) comparing the combination of norepinephrine plus vasopressin receptor agonists versus norepinephrine alone in septic shock patients. Two reviewers independently extracted data on mortality, ICU length of stay, renal replacement therapy (RRT) and adverse events. Trial sequential analysis (TSA) was applied to assess random error.ResultsTwenty-one RCTs involving 3873 septic shock patients were included. The results showed that the combination of norepinephrine plus vasopressin receptor agonists was associated with lower mortality at the longest complete follow-up compared with norepinephrine alone (RR = 0.90, 95% CI 0.83 to 0.99, P = .02), but with an increased risk of digital ischemia (RR = 2.21, 95% CI 1.15 to 4.27, P = .02). Subgroup analysis indicated that the combination of norepinephrine plus vasopressin receptor agonists may provide survival benefits for more severe septic shock patients (RR = 0.90, 95% CI 0.81 to 1.00, P = .04). Moreover, compared with norepinephrine alone, the combination of norepinephrine plus vasopressin showed a trend towards reducing the longest follow-up mortality (RR = 0.89, 95% CI 0.80 to 1.00, P = .05). TSA indicated lack of firm evidence for a beneficial effect.ConclusionsIn adults with septic shock, the combination of norepinephrine plus vasopressin receptor agonists may reduce mortality at the longest complete follow-up compared with norepinephrine alone (low quality of evidence), but may increase risk of digital ischemia (low quality of evidence). This benefit mainly appeared in more severe septic shock patients. Moreover, norepinephrine plus vasopressin may confer a survival advantage.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.